[Infectious complications and misuse of high-dose buprenorphine].
BACKGROUND
High-dose buprenorphine (HDB) treatment began in France in 1996 according to relatively unrestricted prescription rules. Continued heroin injection by patients on HDB maintenance treatment and even HDB injection remain underestimated and may lead to a variety of infectious diseases.


OBJECTIVE
Description of infectious complications occurring in patients receiving HDB maintenance treatment.


METHODS
Retrospective study of drug addicts receiving HDB maintenance treatment, injecting (or highly suspected of injecting) it, and hospitalized for infections (other than HIV or viral hepatitis) in the department of infectious and tropical diseases in Nancy University Hospital. Data collection covered 1998 through 2003.


RESULTS
We identified 21 case reports, 9 concerning infectious endocarditis, 8 cutaneous abscesses, 2 osteoarticular infections, 1 meningitis and 1 Candida retinitis. The sex-ratio was of 1 woman for 2 men, and the patients' mean age was 29.8 years. Globally 13 patients had systemic infections. Nine patients admitted having injected HDB (and no other drugs) (including the case of Candida retinitis), while in the other 12 cases, the patients continued injecting heroin as well. The role of misused HDB was strongly suspected in those 12 infections, but was not clearly confirmed. All patients recovered from the infections. The long-term psychosocial outcome remains unknown.


CONCLUSIONS
The cases analyzed illustrate the dual reality that HDB is often ineffective as a maintenance treatment, since some patients continue to inject heroin, and that its misuse can have infectious consequences. The results of HDB maintenance treatment substitution are mixed. The individual benefit/risk ratio must be improved. Networking is crucial, notably between physician and pharmacist, and the monitoring system must be reinforced.
Cazorla
C
C
Service des maladies infectieuses et tropicales, CHU de Nancy (54).
Grenier de Cardenal
D
D
Schuhmacher
H
H
Thomas
L
L
Wack
A
A
May
T
T
Rabaud
C
C
D000038:Abscess / Q000139:chemically induced; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects*; D002047:Buprenorphine / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004697:Endocarditis, Bacterial / Q000139:chemically induced*; D005260:Female; D006556:Heroin Dependence / Q000534:rehabilitation*; D006801:Humans; D008297:Male; D008581:Meningitis / Q000139:chemically induced; D010019:Osteomyelitis / Q000139:chemically induced; D012173:Retinitis / Q000139:chemically induced; D012189:Retrospective Studies; D012871:Skin Diseases / Q000139:chemically induced; D015819:Substance Abuse, Intravenous / Q000150:complications*
D000701:Analgesics, Opioid; D002047:Buprenorphine